Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement Disorders

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics, Inc. (Nasdaq: SAGE) announced that they have executed a global collaboration and license agreement to jointly develop and commercialize zuranolone (SAGE-217) for major depressive disorder (MDD), postpartum depression (PPD) and other psychiatric disorders and SAGE-324 for essential tremor and other neurological disorders.

2 thoughts on “Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement Disorders

  1. Hi
    I was diagnosed with ET in my 20 my tremor is affecting my every day living. Medication is not helping. Would there be any trials that are suitable. I am in my late 30.

    Sincerely yours,

    Jessica Katan

Comments are closed.